Table 1

Baseline characteristics of study patients

Control (n=29)Buteyko (n=30)PCLE (n=30)
Values are mean (SD) unless stated otherwise.
PCLE=Pink City Lung Exerciser; FEV1=forced expiratory volume in 1 second; PD20=dose of methacholine provoking a fall in FEV1 of 20% or more.
*More detailed quality of life baseline measurements are available online in table 1b at www.thoraxjnl.com/supplemental.
Age (years)47 (11)40 (11)45 (13)
M/F18/1115/1516/14
Inhaled corticosteroid dose (μg)603 (330)757 (370)608 (529)
Never/ex-smokers16/1320/1015/15
Duration of asthma (years)23 (15.3)24 (14.7)23 (14.1)
FEV1 (l)2.71 (0.89)2.58 (0.76)2.64 (0.94)
FEV1 (% predicted)82 (21.1)77 (16.4)80 (17.6)
Reversibility (%)17 (8.3)19 (13.3)16 (6.2)
Median (IQR) β2 agonist use (puffs/day)2 (0–3.8)2 (0–4)2 (0–4)
Geometric mean (IQR) PD20 methacholine (μmol)0.66 (0.2–2.1)0.19 (0.07–0.6)0.65 (0.2–2.8)
Median (IQR) symptom score3.5 (2–5.8)4 (2.8–5.3)4 (3–6)
Overall asthma quality of life score*5.0 (0.8)5.1 (1.0)4.9 (0.8)